BioNTech Full Year 2023 Earnings: Misses Expectations [Yahoo! Finance]
BioNTech SE - American Depositary Shares (BNTX)
Company Research
Source: Yahoo! Finance
Net income: €930.3m (down 90% from FY 2022). Profit margin: 24% (down from 55% in FY 2022). The decrease in margin was driven by lower revenue. EPS: €3.87 (down from €38.78 in FY 2022). BNTX Products In Clinical Trials Phase I: 13. Phase II: 10. Phase III: 5. All figures shown in the chart above are for the trailing 12 month (TTM) period BioNTech Revenues and Earnings Miss Expectations Revenue missed analyst estimates by 8.8%. Earnings per share (EPS) also missed analyst estimates by 14%. In the last 12 months, the only revenue segment was Pharmaceuticals contributing €3.82b. The largest operating expense was Research & Development (R&D) costs, amounting to €1.78b (78% of total expenses). Explore how BNTX's revenue and expenses shape its earnings. Looking ahead, revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The com
Show less
Read more
Impact Snapshot
Event Time:
BNTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTX alerts
High impacting BioNTech SE - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BNTX
News
- CureVac N.V. (NASDAQ:CVAC) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Scholz promises support for pharma sector in Germany as Merck invests [Reuters]Reuters
- Scholz promises support for pharma sector in Germany as Merck invests [Yahoo! Finance]Yahoo! Finance
- BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024GlobeNewswire
- BioNTech SE (NASDAQ: BNTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $107.00 price target on the stock.MarketBeat
BNTX
Earnings
- 3/20/24 - Miss
BNTX
Sec Filings
- 4/8/24 - Form 6-K
- 4/8/24 - Form 6-K
- 3/25/24 - Form 6-K
- BNTX's page on the SEC website